Infinity halts drug trials, shares fall

(Reuters) – Infinity Pharmaceuticals stopped two mid-stage trials of its experimental drug to treat a rare bone marrow disorder and a type of bone cancer, sending its shares down as much as 21 percent. This is not the first time that Infinity is facing disappointment with the drug saridegib. In January, the company had stopped another trial in which the drug was being studied as a treatment for pancreatic cancer. …